321 results
8-K
EX-99.1
LFCR
Lifecore Biomedical Inc
16 May 24
Lifecore Biomedical Completes Incremental Liquidity Initiatives
4:48pm
independent auditor, BDO, as we seek to get current on our public filings as promptly as possible, and successfully closing out our fiscal year
8-K
EX-10.1
LFCR
Lifecore Biomedical Inc
14 May 24
Entry into a Material Definitive Agreement
5:04pm
12.02 Rights of Lenders 187189 12.03 Certain Waivers 187189 12.04 Obligations Independent 189191 12.05 Subrogation 189191 12.06 Termination … the Maturity Date; provided, however, that (i) with respect to any Equity Interests issued to any employee, director or individual independent contractor
8-K
LFCR
Lifecore Biomedical Inc
30 Apr 24
Changes in Registrant's Certifying Accountant
5:06pm
. (the “Company”) approved the engagement of BDO USA, P.C. (“BDO”) as the Company’s independent registered public accounting firm, effective immediately
NT 10-Q
LFCR
Lifecore Biomedical Inc
8 Apr 24
Notice of late quarterly filing
4:25pm
LLP (“EY”), the Company’s independent registered public accounting firm for the fiscal year ended May 28, 2023, notified the Company had determined … that it declined to stand for reappointment as the Company’s independent registered public accounting firm for the Company’s fiscal year ending May 26
8-K
EX-99.1
LFCR
Lifecore Biomedical Inc
1 Apr 24
Results of Operations and Financial Condition
8:07am
. No independent registered public accounting firm has audited, reviewed, compiled or applied agreed-upon procedures with respect to these preliminary
8-K
EX-99.2
crg n4knfjbhwhh
1 Apr 24
Results of Operations and Financial Condition
8:07am
8-K
qq2exavdf gk8
26 Mar 24
Changes in Registrant's Certifying Accountant
4:32pm
8-K
EX-99.1
bz7ykc
20 Mar 24
Lifecore Biomedical Concludes Strategic Evaluation Process, Announces Management Succession and Board Changes
6:32pm
8-K
EX-10.3
ubv4ec hy
20 Mar 24
Lifecore Biomedical Concludes Strategic Evaluation Process, Announces Management Succession and Board Changes
6:32pm
8-K
EX-10.2
pe21kj2964rbdfys8w
20 Mar 24
Lifecore Biomedical Concludes Strategic Evaluation Process, Announces Management Succession and Board Changes
6:32pm
8-K
EX-10.3
x23i akropx
5 Jan 24
Entry into a Material Definitive Agreement
4:09pm
8-K
7uoj wl8v88
31 Oct 23
Non-Reliance on Previously Issued Financial Statements or a Related Audit Report or Completed Interim Review
6:17am
424B3
00nd 4inn7ks0
9 Jun 23
Prospectus supplement
4:31pm
S-1/A
g6o7liq
6 Jun 23
IPO registration (amended)
4:54pm
S-1/A
EX-23.1
jhctw59gvv667bd 03
6 Jun 23
IPO registration (amended)
4:54pm
8-K
EX-10.1
4ai07 iz5
22 May 23
New $150 million credit arrangements include six-year credit agreement and equipment sale and leaseback to replace existing term loan
9:57pm